XML 96 R37.htm IDEA: XBRL DOCUMENT
v3.20.4

Alcon subsidiaries | 12 Months Ended
--- | ---
Dec. 31, 2020
Disclosure Of Separate Financial Statements [Abstract] |
Alcon subsidiaries | Alcon subsidiaries The following table lists the subsidiaries of Alcon Inc. with Total assets or Net sales to third parties in excess of $5 million included in the Consolidated Financial Statements at and for the year ended December 31, 2020, respectively. The equity interest percentage shown in the table represents Alcon's share in voting rights in those entities. Unless otherwise stated, each entity has share capital consisting of equity held directly by the Company or another of its consolidated subsidiaries.
Country of organization/Entity name | Place of business | Equity interest
Argentina |  |
Alcon Laboratorios Argentina S.A. | Buenos Aires | 100 | %
Australia |  |
Alcon Laboratories (Australia) Pty Ltd | Frenchs Forest, NSW | 100 | %
Austria |  |
Alcon Ophthalmika GmbH | Wein | 100 | %
Belgium |  |
Alcon Laboratories Belgium BVBA | Puurs | 100 | %
N.V. Alcon S.A. | Vilvoorde | 100 | %
Brazil |  |
Alcon Brasil Cuidados com a Saúde Ltda. | São Paulo | 100 | %
Canada |  |
Alcon Canada Inc. | Mississauga, Ontario | 100 | %
Chile |  |
Alcon Laboratorios Chile Ltd. | Santiago de Chile | 100 | %
China |  |
Alcon (China) Ophthalmic Product Co., Ltd. | Beijing | 100 | %
Alcon Hong Kong Limited | Hong Kong | 100 | %
Colombia |  |
Laboratorios Alcon de Colombia S.A. | Santafé de Bogotá | 100 | %
Czech Republic |  |
Alcon Pharmaceuticals (Czech Republic) s.r.o. | Prague | 100 | %
Denmark |  |
Alcon Nordic A/S | Copenhagen | 100 | %
Ecuador |  |
AlconLab Ecuador S.A. | Quito | 100 | %
France |  |
Laboratoires Alcon S.A.S. | Rueil-Malmaison | 100 | %
Germany |  |
Alcon Deutschland GmbH | Freiburg im Breisgau | 100 | %
CIBA Vision GmbH | Grosswallstadt | 100 | %
WaveLight GmbH | Erlangen | 100 | %
Greece |  |
Alcon Laboratories Hellas- Single Member Commercial and Industrial S.A.C.I. | Maroussi, Athens | 100 | %
Hungary |  |
Alcon Hungary Pharmaceuticals Trading Limited Liability Company | Budapest | 100 | %
India |  |
Alcon Laboratories (India) Private Limited | Bangalore | 100 | %
Indonesia |  |
PT. CIBA Vision Batam | Batam | 100 | %
Ireland |  |
Alcon Laboratories Ireland Limited | Cork City | 100 | %
Israel |  |
Optonol Ltd. | Neve-Ilan | 100 | %
Italy |  |
Alcon Italia S.p.A. | Milano | 100 | %
Japan |  |
Alcon Japan Ltd. | Tokyo | 100 | %
Country of organization/Entity name | Place of business | Equity interest
Malaysia |  |
Alcon Laboratories (Malaysia) Sdn. Bhd. | Petaling Jaya | 100 | %
CIBA Vision Johor Sdn. Bhd. | Kuala Lumpur | 100 | %
Mexico |  |
Alcon Laboratorios, S.A. de C.V. | Ciudad de Mexico | 100 | %
Netherlands |  |
Alcon Nederland B.V. | Arnhem | 100 | %
New Zealand |  |
Alcon Laboratories (New Zealand) Ltd. | Auckland | 100 | %
Panama |  |
Alcon Centroamerica S.A. | Panama City | 100 | %
Peru |  |
Alcon Pharmaceutical del Peru S.A. | Lima | 100 | %
Philippines |  |
Alcon Laboratories (Philippines), Inc. | Manila | 100 | %
Poland |  |
Alcon Polska Sp. z o.o. | Warszawa | 100 | %
Portugal |  |
Alcon Portugal-Produtos e Equipamentos Oftalmológicos Lda. | Porto Salvo | 100 | %
Puerto Rico |  |
Alcon (Puerto Rico), Inc. | Cataño, PR | 100 | %
Romania |  |
Alcon Romania S.R.L. | Bucharest | 100 | %
Russian Federation |  |
Alcon Farmacevtika LLC | Moscow | 100 | %
Singapore |  |
Alcon Pte Ltd | Singapore | 100 | %
Alcon Singapore Manufacturing Pte Ltd | Singapore | 100 | %
CIBA Vision Asian Manufacturing and Logistics Pte Ltd. | Singapore | 100 | %
South Africa |  |
Alcon Laboratories (South Africa) (Pty) Ltd. | Midrand | 100 | %
South Korea |  |
Alcon Korea Ltd. | Seoul | 100 | %
Spain |  |
Alcon Healthcare S.A. | Barcelona | 100 | %
Switzerland |  |
Alcon Grieshaber AG | Schaffhausen | 100 | %
Alcon Management SA | Vernier | 100 | %
Alcon Pharmaceuticals Ltd. | Fribourg | 100 | %
Alcon Services AG | Fribourg | 100 | %
Alcon Switzerland SA | Zug | 100 | %
Thailand |  |
Alcon Laboratories (Thailand) Limited | Bangkok | 100 | %
Turkey |  |
Alcon Laboratuvarlari Ticaret A.S. | Istanbul | 100 | %
Ukraine |  |
Alcon Ukraine LLC | Kiev | 100 | %
United Kingdom |  |
Alcon Eye Care UK Limited | Frimley/Camberley | 100 | %
United States of America |  |
Alcon Finance Corporation | Fort Worth, TX | 100 | %
Alcon Laboratories, Inc. | Fort Worth, TX | 100 | %
Alcon RefractiveHorizons, LLC | Fort Worth, TX | 100 | %
Alcon Research, LLC | Fort Worth, TX | 100 | %
Country of organization/Entity name | Place of business | Equity interest
Alcon Vision, LLC | Fort Worth, TX | 100 | %
CIBA Vision, LLC | Fort Worth, TX | 100 | %
WaveLight, Inc. | Fort Worth, TX | 100 | %
ClarVista Medical, Inc. | Fort Worth, TX | 100 | %
PowerVision, Inc. | Fort Worth, TX | 100 | %
Tear Film Innovations, Inc. | Fort Worth, TX | 100 | %
TrueVision Systems, Inc. | Fort Worth, TX | 100 | %
Alcon LenSx, Inc. | Fort Worth, TX | 100 | %
During the year ended December 31, 2020, the below principal Novartis legal entity contained assets, liabilities and results of operations attributable to the Alcon business with Total assets or Net sales to third parties in excess of $5 million included in the Consolidated Financial Statements.
Mexico
Novartis Farmacéutica, S.A. de C.V.

X
- Definition Disclosure Of Separate Financial Statements [Abstract] + References No definition available. + Details
Name: | alc_DisclosureOfSeparateFinancialStatementsAbstract
Namespace Prefix: | alc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of subsidiaries. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2020-01-01 -Paragraph 17 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_17_b&doctype=Standard -URIDate 2020-01-01 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2020-01-01 -Paragraph 16 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_16_b&doctype=Standard -URIDate 2020-01-01 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2020-01-01 -Paragraph B4 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B -URIDate 2020-01-01 + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration